CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
Wonyoung Choi, Seog-Yun Park, Youngjoo Lee, Kun Young Lim, Minjoung Park, Geon Kook Lee, Ji-Youn Han
Cancer Research and Treatment. 2021;53(4):1024-1032.   Published online 2021 January 29    DOI: https://doi.org/10.4143/crt.2020.1331

Excel Download

The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
Cancer Research and Treatment. 2021;53(4):1024-1032   Crossref logo
Link1 Link2 Link3

Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies
Cancer Treatment Reviews. 2021;95:102173   Crossref logo
Link1 Link2

MET Immunohistochemistry Should Be Avoided in Selecting Non–small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis
Clinical Lung Cancer. 2019;20(3):e418-e420   Crossref logo
Link1 Link2

Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14
Thoracic Cancer. 2020;12(4):549-552   Crossref logo
Link1 Link2 Link3

MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy
Lung Cancer. 2021;154:142-145   Crossref logo
Link1 Link2

P85.05 MET Exon 14 Skipping Mutation Positive Non-Small Cell Lung Cancer: A Population-Based Cohort
Journal of Thoracic Oncology. 2021;16(3):S670-S671   Crossref logo
Link1 Link2

Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States
Journal of Medical Economics. 2021;24(1):131-139   Crossref logo
Link1

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
Cancer Treatment Reviews. 2020;87:102022   Crossref logo
Link1 Link2

OA06 Tepotinib in Non-Small Cell Lung Cancer with MET Exon 14-Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress
Journal of Thoracic Oncology. 2018;13(12):S1046   Crossref logo
Link1 Link2

Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); A phase II trial in progress
Annals of Oncology. 2018;29:ix169   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.